Svb Leerink Initiates Coverage on Tcr2 Therapeutics (TCRR)
Svb Leerink started coverage on shares of Tcr2 Therapeutics (NASDAQ:TCRR) in a research note released on Monday, MarketBeat.com reports. The firm issued an outperform rating and a $27.00 price target on the stock. Svb Leerink also issued estimates for Tcr2 Therapeutics’ Q4 2018 earnings at ($0.38) EPS, FY2018 earnings at ($6.08) EPS, Q1 2019 earnings at ($0.45) EPS, Q2 2019 earnings at ($0.47) EPS, Q3 2019 earnings at ($0.49) EPS, Q4 2019 earnings at ($0.52) EPS, FY2019 earnings at ($1.93) EPS, FY2020 earnings at ($2.65) EPS, FY2021 earnings at ($2.85) EPS and FY2022 earnings at ($3.05) EPS.
Other research analysts also recently issued research reports about the stock. Jefferies Financial Group started coverage on shares of Tcr2 Therapeutics in a research note on Monday. They issued a buy rating and a $31.00 price target for the company. Wedbush started coverage on shares of Tcr2 Therapeutics in a research note on Monday. They issued an outperform rating and a $28.00 price target for the company. They noted that the move was a valuation call. Leerink Swann initiated coverage on shares of Tcr2 Therapeutics in a research note on Monday. They issued an outperform rating for the company. Finally, BMO Capital Markets initiated coverage on shares of Tcr2 Therapeutics in a research report on Monday. They set an outperform rating and a $37.00 price objective for the company. Five analysts have rated the stock with a buy rating, The stock has an average rating of Buy and a consensus target price of $30.75.
Shares of Tcr2 Therapeutics stock opened at $18.24 on Monday. Tcr2 Therapeutics has a 52-week low of $14.80 and a 52-week high of $25.47.
About Tcr2 Therapeutics
TCR2 Therapeutics Inc, a clinical-stage immunotherapy company, develops novel T cell receptor therapies for patients suffering from cancer. Its product candidates in pipeline comprise TC-210 mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors; TC-220 that targets MUC16 positive solid tumors; and TC-310 and TC-410 dual TRuC-T cell programs targeting CD19/22 and MSLN/MUC16, as well as TC-110 mono TRuC-T cells targeting CD19-positive B-Cell hematological malignancies.
Featured Article: Return on Investment (ROI) Defined, Explained
Receive News & Ratings for Tcr2 Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tcr2 Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.